$AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Brian Goff
CEO
486
Employees
$38.12
Current Price
$1.61B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $296,469.54 | 7,866 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 3 | $371,111.71 | 9,855 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 3 | $371,111.71 | 9,855 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 3 | $371,111.71 | 9,855 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 4 | $1,285,511.71 | 39,855 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Oct 26, 2026 | Gheuens Sarah Chief Medical Officer | Sale | 7,866 | $37.69 | $296,469.54 | View Details |
| Oct 21, 2026 | Gheuens Sarah Chief Medical Officer | Sale | 1,489 | $37.53 | $55,882.17 | View Details |
| Oct 22, 2026 | Gheuens Sarah Chief Medical Officer | Sale | 500 | $37.52 | $18,760.00 | View Details |
| Aug 4, 2026 | Gheuens Sarah Chief Medical Officer | Sale | 30,000 | $30.48 | $914,400.00 | View Details |
39 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$1.24
ActualN/A
Revenue
Estimated$51.65M
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$1.24
ActualN/A
Revenue
Estimated$53.36M
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history